Point72 Asset Management, L.P. ownership in CPRX / Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

US ˙ NasdaqCM ˙ US14888U1016

Security	CPRX / Catalyst Pharmaceuticals, Inc.
Institution	Point72 Asset Management, L.P.
Manager	Steven Cohen
Latest Disclosed Ownership	2,276,923 shares
Ownership	2.70%

2016-02-16 - Point72 Asset Management, L.P. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,276,923 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX). This represents 2.7 percent ownership of the company.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2016-02-16	2016-02-16	13G/A		2,276,923		2.70
2014-12-02	2014-12-02	13G		3,500,000		5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	425,865	425,865		10,544		0.0135
2024-11-14	2024-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	0	-618,296	-100.00	0	-100.00
2024-09-16	2024-06-30	13F/A-2	CATALYST PHARMACEUTICALS	COM	14888U101	618,296	200,370	47.94	9,577	43.78	0.0251
2024-08-19	2024-06-30	13F/A-1	CATALYST PHARMACEUTICALS	COM	14888U101	618,296	200,370		9,577		0.0251
2024-08-14	2024-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	618,296	200,370		9,577		0.0250
2024-05-15	2024-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	417,926	-78,665	-15.84	6,662	-20.20	0.0161
2024-02-14	2023-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	496,591	300,280	152.96	8,348	263.86	0.0202
2023-11-14	2023-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	196,311	196,311		2,295		0.0067
2023-08-14	2023-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	0	-1,470	-100.00	0	-100.00
2023-05-15	2023-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	1,470	1,470		24		0.0001
2021-02-16	2020-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	0	-50,000	-100.00	0	-100.00
2020-11-16	2020-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	50,000	50,000		149		0.0008
2017-08-14	2017-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	0	-877,266	-100.00	0	-100.00
2017-05-15	2017-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	877,266	-1,395,550	-61.40	1,711	-28.29	0.0095
2017-02-14	2016-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,272,816	-94,148	-3.98	2,386	-7.52	0.0167
2016-11-14	2016-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,366,964	0	0.00	2,580	53.48	0.0181
2016-08-15	2016-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,366,964	103,388	4.57	1,681	-36.52	0.0114
2016-05-16	2016-03-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,263,576	-13,347	-0.59	2,648	-52.53	0.0203
2016-02-16	2015-12-31	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,276,923	70,659	3.20	5,578	-15.73	0.0460
2015-11-16	2015-09-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	2,206,264	-1,257,541	-36.31	6,619	-53.73	0.0520
2015-08-14	2015-06-30	13F	CATALYST PHARMACEUTICALS	COM	14888U101	3,463,805	-3,104,195	-47.26	14,306	-49.70	0.0991
2015-05-15	2015-03-31	13F	CATALYST PHARM PARTNERS	COM	14888U101	6,568,000	3,068,000	87.66	28,439	173.58	0.1938
2015-02-17	2014-12-31	13F	CATALYST PHARM PARTNERS	COM	14888U101	3,500,000	3,500,000		10,395		0.0729

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.